Key result
Omapatrilat and captopril prevented mortality (0% vs ~90% with L-NAME alone) and induced complete regression of renal injury in nitric oxide-deficient rats on a normal-sodium diet.
Why the study?
Does omapatrilat induce better regression of renal injury than captopril in nitric oxide-deficient rats on normal or high sodium diets?
Population
Nitric oxide-deficient rats fed either a normal or high sodium diet.
Comparison
Omapatrilat plus L-NAME for 4 weeks. vs Captopril plus L-NAME, or L-NAME alone for 4…
Design
Preclinical
Follow-up
8 weeks (4 weeks induction + 4 weeks treatment)
Authors
Loading...
ACE/vasopeptidase inhibitors show renoprotective potential in this rat model; hypothesis-generating for human renal disease and blunted by high sodium.
Does omapatrilat induce better regression of renal injury than captopril in nitric oxide-deficient rats on normal or high sodium diets?
Absolute Event Rate: 0% vs 90%
ACE and vasopeptidase inhibitors exhibit marked renoprotective and antihypertensive effects in nitric oxide-deficient rats on a normal sodium diet, but efficacy is blunted by a high sodium diet.
Lü et al. (2003) studied Systemic hypertension and renal injury. Omapatrilat vs. Captopril (200 mg x kg(-1) x d(-1)) or L-NAME alone was evaluated on Mortality rate. Omapatrilat and captopril prevented mortality (0% vs ~90% with L-NAME alone) and induced complete regression of renal injury in nitric oxide-deficient rats on a normal-sodium diet.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: